101 Arch Street
`Suite 1010
`Boston, MA 02110
`
`t: 617.995.7676
`f: 617.995.7677
`
`
`
`
`
`
`
`
`CHRISTOPHER A. VELLTURO
`President
`
`Over the course of his career, Dr. Vellturo has performed a wide variety of economic and econometric analyses
`
`and provided expert testimony in the context of mergers and acquisitions, antitrust litigation, intellectual
`
`property litigation and numerous other matters spanning a broad array of industries. Dr. Vellturo has testified
`
`on economics-related matters in numerous U.S. District Courts, as well as at the Canadian Competition Bureau,
`
`and the American Arbitration Association. He has appeared before the U.S. Department of Justice, the Federal
`
`Trade Commission, various states’ Attorneys General offices, the Federal Reserve Bank Board of Governors,
`
`and numerous other regulatory agencies on merger-related issues and other antitrust matters. Dr. Vellturo has
`
`also made appearances at hearings before the European Commission, and other antitrust enforcement agencies
`
`around the world. To date, he has performed economic analyses in over one hundred merger matters, in excess
`
`of seventy antitrust actions and well over one hundred intellectual property actions.
`
`Dr. Vellturo has taught graduate-level economics at Boston University’s School of Management.
`
`Prior to forming Quantitative Economic Solutions, LLC (QES), Dr. Vellturo was a Principal at Analysis
`
`Group/Economics (AG/E) and a Senior Vice President and member of the Board of Directors at National
`
`Economic Research Associates (NERA).
`
`Dr. Vellturo has published on a variety of topics, including merger and acquisition-related efficiencies, price
`
`discrimination, differentiated product analysis and market definition. His research has appeared in leading
`
`academic journals, including Antitrust, the Antitrust Law Journal, and the Journal of Economics and Management
`
`Strategy. Dr. Vellturo is a recipient of the Bradley Fellowship in Public Economics and has served as a referee
`
`for American Economic Review and Rand Journal of Economics.
`
`A Ph.D. graduate in Economics from the Massachusetts Institute of Technology, Dr. Vellturo also holds a
`
`Sc.B. in Applied Mathematics and Economics from Brown University, where he graduated magna cum laude and
`
`Phi Beta Kappa.
`
`
`
`
`JANSSEN EXHIBIT 2045
`Mylan v. Janssen IPR2016-01332
`
`

`

`Christopher A. Vellturo, page 2
`
`EDUCATION
`
`1989
`
`
`
`Ph.D. in Economics, Massachusetts Institute of Technology
`Primary Fields: Econometrics, Industrial Organization
`Secondary Fields: Public Finance, Game Theory, Law and Economics
`
`
`1983
`
`
`
`Sc.B. in Applied Mathematics and Economics (magna cum laude), Brown University
`
`PROFESSIONAL EXPERIENCE
`
`2008-Present Boston University, School of Management
`Instructor – Department of Finance & Economics
`
`2000-2002
`
`
`2002-Present Quantitative Economic Solutions, LLC
`President/Manager – Direct research on microeconomic issues in litigation and non-
`litigation matters. Areas of particular focus include: antitrust, regulation, and damages
`assessment in intellectual property and contract matters.
`
`Analysis Group/Economics
`Principal - Direct research and provide expert testimony on a variety of
`microeconomic issues with particular emphasis on antitrust, intellectual property, and
`mergers and acquisitions. Expert reports and testimony presented in U.S. District
`Court. Presented antitrust economic analyses to Federal Trade Commission, U.S.
`Department of Justice, Federal Reserve Bank Board of Governors and the European
`Commission.
`
`
`1996-2000
`
`
`
`
`
`1991-1996
`
`
`1989-1991
`
`National Economic Research Associates, Inc.
`Senior Vice President (1999-2000)
`Vice President (1996-1999)
`
`Cambridge Economics, Inc.
`Director - Directed research and provided expert testimony on a variety of
`microeconomic issues with particular emphasis on antitrust, intellectual property, and
`mergers and acquisitions. Prior expert testimony provided in U.S. District Court and
`before the American Arbitration Association. Presented antitrust economic analyses
`to U.S. Department of Justice, Federal Trade Commission (Antitrust Division), state
`Attorneys General offices, and the Federal Reserve Bank Board of Governors.
`
`National Economic Research Associates, Inc.
`Senior Consultant - Directed and performed research relating to issues of antitrust,
`intellectual property, mergers and regulation.
`
`
`
`
`Department of Economics, M.I.T.
`Teaching Assistant - Undergraduate econometrics.
`
`
`1987
`
`
`
`
`

`

`Christopher A. Vellturo, page 3
`
`1985-1989
`
`1983-1985
`
`Dean Ann F. Friedlaender, M.I.T.
`Research Associate - Participated in research relating to transportation pricing and
`capital allocation responses to regulatory changes.
`
`
`National Economic Research Associates, Inc.
`Research Associate - Conducted research on a wide variety of issues including antitrust,
`railroad rate setting, optimal landfill pricing, and PCB and asbestos abatement
`strategies.
`
`
`
`AWARDS AND PROFESSIONAL ACTIVITIES
`
`1987-1989
`
`Recipient, Bradley Fellowship in Public Economics
`
`1986
`
`1983
`
`1983
`
`
`
`
`
`
`
`Present
`
`Present
`
`Present
`
`
`
`
`
`M.I.T. Departmental Fellowship
`
`Phi Beta Kappa, Brown University
`
`Sigma Xi, Brown University
`
`Journal Referee for American Economic Review and Rand Journal of Economics
`
`Member, American Economic Association
`
`Member, American Bar Association
`
`
`
`

`

`Christopher A. Vellturo, page 4
`
`TESTIFYING HISTORY (PAST FOUR YEARS)
`
`
`
` Erfindergemeinschaft UroPep GbR v. Eli Lilly and Company, and Brookshire Brothers, Inc.
`United States District Court for the Eastern District of Texas
`Civil No. 2:15-cv-01202-JRG
`
`In re: Biogen ‘755 Patent Litigation
`United States District Court for the District of New Jersey
`Civil Action No. 10-cv-02734(CCC) (JAD)
`
` ViaTech Technologies, Inc. v. Microsoft Corporation
`United States District Court for the District of Delaware
`C.A. No. 1:14-1226-RGA
`
` 
`
` Amerigen Pharmaceuticals Limited and Argentum Pharmaceuticals LLC Petitioners, v Janssen Oncology, Inc.,
`Patent Owner
`Case No. IPR2016-00286 U.S. Patent No. 8,822,438 B2
`
` Arthrex Inc. v. Smith & Nephew, Inc. and Arthrocare Corp; Arthrex Inc. v. Smith & Nephew, Inc. and
`Arthocare Corp.
`U.S. District Court for the Eastern District of Texas, Marshall Division, Civil Action Nos. 2:15-
`cv-1047-RSP and 2:15-cv-1756-RSP.
`
` Crane Security Technologies, Inc., and Visual Physics, LLC., v. Rolling Optics AB
`U.S. District Court for the District of Massachusetts, C.A. No. 14-cv-12428-LTS
`
` Argentum Pharmaceuticals LLC, v. Research Corporation Technologies, Inc.
`U.S. Patent and Trademark Office Before the Patent Trial and Appeal Board, Case No.
`IPR2016-00204
`
` Bristol-Myers Squibb Co., E.R. Squibb & Sons LLC, ONO Pharmaceutical Co., Ltd., and Tasuku Honjo
`v. Merck & Co., Inc. and Merck Sharp & Dohme Corp.
`U.S. District Court for the District of Delaware, Civil Action Numbers 14-1131-GMS; 14-560-
`GMS; 15-572-GMS
`
` 
`
` Koninklijke Phillips N.V. and Philips Electronics North America Corporation v. ZOLL LifeCor
`Corporation.
`U.S. District Court, District of Western Pennsylvania, Consolidated Civil Action No. 2:12-cv-
`01369-NBF
`
` Enzo Life Sciences, Inc. v. Roche Molecular Systems, lnc.
`U.S. District Court, district of Delaware, Case No. 12 Civ. 106.
`
` Enzo Life Sciences, Inc. v. Becton, Dickinson and Company, Becton Dickinson Diagnostics, Inc., and Geneohm
`Sciences, Inc.
`U.S. District Court, District of Delaware, Consolidated Civil Action No. 12-275-LPS
`
`

`

`Christopher A. Vellturo, page 5
`
` Merck Sharp & Dohme Corp, v. Hospira, Inc.
`U.S. District Court, District of Delaware, Consolidated Civil Action No. 14-915-RGA
`
` Gilead Sciences, Inc., Gilead Pharmasset LLC and Gilead Sciences Limited v. AbbVie Inc., and AbbVie
`Ireland Unlimited Company
`U.S. District Court, District of Delaware, Consolidated Civil Action No. 13-2034-GMS
`
` MSC. Software Corporation v. Altair Engineering, Incorporated et al.
`U.S. District Court, Eastern District of Michigan Southern Division, Case No. 2:07-cv-12807
`
` UCB, Inc., UCB Pharma GMBH, Research Corporation Technologies, Inc. and Harris FRC Corporation v.
`Accord Healthcare, Inc., et al.
`U.S. District Court, District of Delaware, Civil Action No. 1:13-cv-1206-LPS
`
` SAS Institute Inc. v. World Programming Limited
`U.S. District Court, District of North Carolina, Civil Action No. 5:10-cv-00025-FL (E.D.N.C.)
`
`
`
`In Re: Certain Consolidated Zoledronic Acid Cases
`U.S. District Court, District of New Jersey, Consolidated Civil Action No. 12-03967 (SDW)
`(SCM) [Consolidated with Civil Action Nos. 12-cv-04393, 13-cv-01028, 13-cv-02379, 13-cv-
`4669, 13-cv-5125, 13-cv-6835, 13-v-7914, and 14-cv-1841]
`
` Ronald A. Katz Technology Licensing L.P. v. FedEx Corporation, Federal Express Corporation, FedEx
`Corporate Services, INC., and FedEx Customer Information Services, Inc.
`U.S. District Court, Western District of Tennessee, Case No. 2:15-cv-02329-JPM-tmp
`
`
`
`Janssen Pharmaceuticals, INC ., et al v. Actavis Elizabeth LLC, et al.,
`U.S. District Court, District of New Jersey, Civil Action No. 2:13-cv-04507-CCC-MF
`
` Unimed Pharmaceuticals, LLC, Besins Healthcare Inc, and Besins Healthcare Luxembourg, Sarl v. Perrigo
`Company and Perrigo Israel Pharmaceuticals LTD
`U.S. District Court, District of Delaware, Consolidated Civil Action No. 13-236 (RGA)
`
` AstraZeneca LP and AstraZeneca AB v. Breath Ltd./AstraZeneca LP and AstraZeneca AB v. Apotex,
`Inc. and Apotex Corp./AstraZeneca LP and AstraZeneca AB v. Sandoz, Inc./AstraZeneca LP and
`AstraZeneca AB v. Watson Laboratories, Inc.
`U.S. District Court, District of New Jersey, Consolidated Civil Action No. 08 CV 1512
`(RMB)(AMD).
`
` L’Oreal S.A. and L’Oreal USA, Inc.v. Merck and Co., Inc., Merck Sharp & Dohme Corp. and MSD
`Consumer Care, Inc.
`U.S. District Court, District of Delaware, Civil Action No. 12-99-GMS.
` Aetna Inc. v. Blue Cross Blue Shield of Michigan,
`U.S. District Court, Eastern District of Michigan, Civil Action No. 2:11-cv-15346-BAF-RSW
`
` Medac Phamra, Inc. and medac Gesellschaft für klinische Spezialpräparate mbH v. Antares Pharma, Inc., Leo
`Pharma A/S and Leo Pharma Inc.,
`U.S. District Court, District of New Jersey, Civil Action No. 1:14-cv-01498-JBS-KMW
`
`

`

`Christopher A. Vellturo, page 6
`
`
` Koninklijke Philips Electronics, N.V. and Philips Electronics North America Corporation v. ZOLL Medical
`Corporation,
`U.S. District Court, District of Massachusetts, Civil Action Nos. 1:10-cv-11041-NMG, 1:12-cv-
`12255-NMG
`
` Bayer Pharma AG, Bayer Intellectual Property GMBH and Bayer Healthcare Pharmaceuticals, INC. v.
`Watson Laboratories, INC.
`U. S. District Court, District of Delaware, Civil Action No. 12-1726 (LPS)(CBJ)
`
` Pfizer Inc., Wyeth LLC, Wyeth Pharmaceuticals Inc. and PF Prism C.V. v. Apotex Inc., et al.
`U.S. District Court, District of Delaware, Civil Action No. 12-808-SLR.
`
` Apple Inc. v. Samsung Electronics Co., et al.
`U.S. District Court, Northern District of California, Case No. 12-CV-00630-LHK.
`
` Stragent, LLC and Seesaw Foundation v. Intel Corporation. U.S. District Court, Eastern District of
`Texas, Tyler Division, Case No. 6:11-CV-421.
`
` Aetna, Inc. v. Blue Cross Blue Shield of Michigan, a Michigan nonprofit healthcare corporation.
`U.S. District Court, District of Michigan, Civil Action No. 2:11-cv-15346-DPH-MKM.
`
` 
`
`In Re: American Express Antisteering Rules Antitrust Litigation (II)
`U.S. District Court, Southern District of New York, Master File No.: 11-MD-02221
`(NGG)(RER).
`
`
`
` 
`
` Altana Pharma AG and Wyeth v. Teva Pharmaceuticals USA, Inc., et al. and Sun Pharmaceuticals
`Industries, Ltd., et al.
`U.S. District Court, District of New Jersey, Consolidated Civil Action Nos. 04-2355 (JLL)
`(MAH)/05-1966 (JLL) (MAH)/05-3290 (JLL) (MAH)/06-3672 (JLL) (MAH).
`
`
`
`
`
`
` 
`
`
`
`
`
`

`

`Christopher A. Vellturo, page 7
`
`PUBLICATIONS AND PRESENTATIONS
`
`“Lunch at Texas Law with Panel of Damages Experts.” Presented at the University of Texas School
`of Law’s Patent Damages Conference, Austin, Texas, June 9, 2016.
`
`“Mock Trial: Carnival Comics, Inc. v. DigiCom, LLP, et al.” Presented at the 61st Annual Spring
`Meeting of the ABA Section of Antitrust Law, Washington, DC, April 11, 2013.
`
`“Understanding How the Patent Cliff Will Re-Define the Endgame.” Presented at the 12th Annual
`Maximizing Pharmaceutical Patent Life Cycles Conference, New York, NY, October 4, 2011.
`
`“Differentiated Products” in Issues in Competition Law and Policy, Volume I, ed. D. Wayne Collins,
`Section of Antitrust Law of the American Bar Association, 2008.
`
`“When Fraud on the Patent Office Violates Section 2: A Mock Trial.” Presented at the 52nd Annual
`Spring Meeting of the ABA Section of Antitrust Law, Washington, DC, April 1, 2004.
`
`“What Drives Consolidation?” Presented at the 28th Semiannual Members Meeting MIT/CRE,
`Cambridge, MA, May 14, 1998.
`
`“Proving Unilateral Effects and Efficiencies in Merger Cases: A Demonstration.” Presented at the
`46th Annual Spring Meeting of the ABA Section of Antitrust Law, Washington, DC, April 1, 1998.
`
`“Creating An Effective Diversion: Evaluating Mergers With Differentiated Products,” Antitrust,
`Spring 1997.
`
`“Economic Battles in the Antitrust Wars: Network Industries and Their Relevance to Antitrust in
`the Computer Industry.” Presented at the Washington State Bar Association’s Thirteenth Annual
`Antitrust, Consumer Protection and Unfair Business Practices Conference, November 8, 1996.
`
`“Differentiated Products: New Tools for New Methods.” Presented at NERA’s Seventeenth
`Annual Antitrust & Trade Regulation Seminar, Santa Fe, NM, July 5, 1996.
`
`“Market Definition Under Price Discrimination” (with J. A. Hausman and G. K. Leonard), Antitrust
`Law Journal, Vol. 64, No. 2 (Winter 1996).
`
`“Learning-by-Doing in the Context of Antitrust Analysis” (with J. Hausman), April 1995.
`
`“An Economic Analysis of ATM Surcharging,” prepared for Southeast Switch Inc., October 5, 1995.
`
`“Cost Effects of Mergers and Deregulation in the U.S. Rail Industry” (with Berndt, et al.), Productivity
`Issues in Services at the Micro Level, ed. Zvi Griliches and Jacques Mairesse, Kluwer Academic
`Publishers, 1993.
`
`“Cost Effects of Mergers and Deregulation in the U.S. Rail Industry” (with Berndt, et al.), Journal of
`Productivity Analysis, 4, 127-144, 1993.
`
`
`

`

`Christopher A. Vellturo, page 8
`
`“Rail Costs and Capital Adjustments in a Quasi-Regulated Environment” (with Friedlaender, et al.),
`Journal of Transport Economics and Policy, 131-152, May 1993.
`
`“Deregulation, Mergers and Cost Savings in Class I U.S. Railroads, 1974-1986” (with Berndt, et al.),
`Journal of Economics and Management Strategy, Vol. 1, No. 2, 1992.
`
`“Observations on Pre-Trial Bargaining Models,” MIT Mimeo, September 1989.
`
`“The Deregulation of the U.S. Rail Industry: Efficiency and Equity in Attaining Rail Viability,” Ph.D.
`Dissertation, Department of Economics, MIT, 1989.
`
`“Achieving Cost Efficiency Through Merger: Evidence from the U.S. Rail Industry,” Presented at the
`American Economic Association Symposium on Mergers and Acquisitions, New York, December 29,
`1988.
`
`